Health
ESMO Guidelines Discourage Delayed, Discontinued Treatment During the COVID-19 Pandemic – OncLive
Any type of anti-cancer therapy that could impact overall survival should not be discontinued or delayed.
Any type of anti-cancer therapy that could impact overall survival (OS) should not be discontinued or delayed, according to a European Society for Medical Oncology (ESMO) interdisciplinary expert consensus paper on how to manage patients with cancer during the coronavirus disease 2019 (COVID-19) pandemic.1
The guidelines, which were recently published in the Annals of Oncology,2 also discourage classifying all patients with cancer as especially vulnerable to COVID-19, regardless of age, gender,…
-
Noosa News18 hours agoFamily pleads for help after 17-year-old Pheobe Bishop disappears in Bundaberg before flight
-
Business19 hours agoASX 200 lifts on the RBA’s latest interest rate call
-
Noosa News21 hours agoNo conviction recorded for teen behind attack on Peter Dutton’s office
-
Noosa News22 hours agoFarmers may lock the gate on renewables in Victoria